| Literature DB >> 26537532 |
Jennifer Stockwell1, Adam D Daniels, Claire L Windle, Thomas A Harman, Thomas Woodhall, Tomas Lebl, Chi H Trinh, Keith Mulholland, Arwen R Pearson, Alan Berry, Adam Nelson.
Abstract
The catalysis of reactions involving fluoropyruvate as donor by N-acetyl neuraminic acid lyase (NAL) variants was investigated. Under kinetic control, the wild-type enzyme catalysed the reaction between fluoropyruvate and N-acetyl mannosamine to give a 90 : 10 ratio of the (3R,4R)- and (3S,4R)-configured products; after extended reaction times, equilibration occurred to give a 30 : 70 mixture of these products. The efficiency and stereoselectivity of reactions of a range of substrates catalysed by the E192N, E192N/T167V/S208V and E192N/T167G NAL variants were also studied. Using fluoropyruvate and (2R,3S)- or (2S,3R)-2,3-dihydroxy-4-oxo-N,N-dipropylbutanamide as substrates, it was possible to obtain three of the four possible diastereomeric products; for each product, the ratio of anomeric and pyranose/furanose forms was determined. The crystal structure of S. aureus NAL in complex with fluoropyruvate was determined, assisting rationalisation of the stereochemical outcome of C-C bond formation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26537532 PMCID: PMC4717870 DOI: 10.1039/c5ob02037a
Source DB: PubMed Journal: Org Biomol Chem ISSN: 1477-0520 Impact factor: 3.876
Fig. 1Examples of fluorinated drugs.
Scheme 1Envisaged strategy for controlling F-bearing stereocentres by C–C bond formation.
Scheme 2Stereoselective aldol reactions catalysed by aldolases generated by directed evolution.[14] The products are drawn in open chain form for clarity.
Scheme 3Reaction between fluoropyruvate and ManNAc catalysed by wild-type NAL. A: The stereochemical outcome is determined by the reaction time. The products are depicted in open chain form for clarity. NAL was regularly added to the 5 week reaction. B: Diastereomeric products that were not observed. C: Cyclised forms of 4a and 4d.
Spectroscopic data for the fluorinated products of aldolase-catalysed reactions
| Product | Form (proportion) |
|
|
|
|
|
2
|
3
|
3
|
3
|
3
|
|
| Major pyranose (98%) | –208.1 | 4.65 | 3.93 | 4.07 | 3.87 | 49.3 | 30.0 | 2.1 | 10.6 | 10.6 |
| Minor pyranose (2%) | –217.9 | NM | NM | NM | NM | 51.3 | 29.9 | NM | NM | NM | |
|
| Major pyranose (96%) | –199.3 | 4.47 | ∼3.90 | ∼3.90 | ∼3.90 | 49.7 | 12.0 | 8.8 | NM | NM |
|
| Major pyranose (92%) | –206.0 | 4.78 | 3.94 | 3.88 | 4.75 | 49.9 | 32.5 | 3.4 | 9.7 | 9.2 |
| Minor pyranose (8%) | –216.8 | NM | NM | NM | NM | 51.4 | 32.8 | NM | NM | NM | |
|
| Major pyranose (35%) | –190.5 | 4.85 | 4.39 | 4.12 | 4.65 | 50.5 | 24.0 | 4.8 | 5.0 | 6.1 |
| Major furanose (25%) | –194.5 | 4.72 | 4.02 | 3.96 | NM | 43.7 | 4.7 | 1.7 | NM | NM | |
| Minor pyranose (30%) | –201.9 | 5.03 | 4.46 | 3.95 | 4.57 | 53.1 | 18.7 | 5.5 | 5.6 | 7.2 | |
| Minor furanose (10%) | –207.4 | 4.86 | 4.30 | 4.18 | 4.75 | 48.5 | 10.1 | 7.3 | NM | 5.4 | |
|
| Pyranose (>98%) | –199.8 | 4.60 | 3.95 | 3.78 | 4.62 | 49.3 | 13.3 | 9.3 | 9.3 | 9.7 |
|
| Major pyranose (98%) | –207.8 | 4.90 | 4.16 | 4.23 | 4.83 | 49.0 | 29.1 | 2.2 | 10.9 | 10.0 |
| Minor pyranose (2%) | –218.5 | NM | NM | NM | NM | 50.2 | 28.8 | NM | NM | NM |
Determined by analysis of the 296 MHz 19F NMR spectrum.
Not measured.
Kinetic parameters for the cleavage of substrates catalysed by wild-type NAL
| Substrate |
|
|
|
| Neu5Ac | 510 ± 10 | 2.0 ± 0.1 | 260 |
|
| 0.91 ± 0.03 | 8.4 ± 0.7 | 0.11 |
|
| ND | ND |
Determined using a coupled enzyme assay involving lactate dehydrogenase.
Not detectable.
Scheme 4Synthesis of precursors of aldehyde substrates. In addition, the alkene ent-15 was prepared from the enantiomeric lactone starting material 11; and 10 was prepared using an established route.[16]
Scheme 5Possible diastereomeric products of aldolase-catalysed reactions with fluoropyruvate as nucleophile.
Activity and selectivity of aldolase variants with fluoropyruvate as donor
| Substrate | Variant | Specific activity | Product | Ratio | (3 |
|
| E192N | 9.1 |
| 40 : 0 : 50 : 10 | 40 : 0 : 50 : 10 |
|
| E192N/T167V/S208V | 0.56 |
| 0 : 0 : 100 : 0 | 0 : 0 : 100 : 0 |
|
| E192N/T167G | 0.06 |
| 30 : 0 : 70 : 0 | 30 : 0 : 70 : 0 |
|
| E192N | 0.46 |
| 10 : 0 : 0 : 90 | 0 : 10 : 90 : 0 |
|
| E192N/T167V/S208V | 0.03 |
| 0 : 0 : 0 : 100 | 0 : 0 : 100 : 0 |
|
| E192N/T167G | 0.12 |
| 20 : 0 : 0 : 80 | 0 : 20 : 80 : 0 |
|
| E192N | 1.1 |
| 60 : 0 : 40 : 0 | 60 : 0 : 40 : 0 |
|
| E192N/T167V/S208V | ND | — | ||
|
| E192N/T167G | 0.03 |
| NM | |
|
| E192N | 0.07 |
| NM | |
|
| E192N/T167V/S208V | ND | — | ||
|
| E192N/T167G | 0.03 |
| NM |
Prepared by ozonolysis of the corresponding alkene (10, ent-10, 15 or ent-15).
Consumption of fluoropyruvate (nmol min–1 per nmol protein) determined by 296 MHz 19F NMR spectroscopy.
Kinetic ratio of diastereomeric products determined by 296 MHz 19F NMR spectroscopy.
Not measured.
Not detectable.
Preparation of fluorinated products of aldolase-catalysed reactions
| Substrate | Variant | Product | Time/day (conversion | Yield |
|
| E192N |
| 2 (>99) | 33 |
|
| E192N/T167 V/S208V |
| 2 (95) | 41 |
|
| E192N/T167 V/S208V |
| 1 (NM | 52 |
|
| E192N |
| 5 (50) | 7 |
Prepared by ozonolysis of the corresponding alkene (10, ent-10, 15 or ent-15).
See Table 1 for details of ratios of anomers and pyranose/furanose forms.
Determined by analysis of the crude product by 296 MHz 19F NMR spectroscopy.
Yield of purified product based on the limiting reactant.
Determined by 296 MHz 19F NMR spectroscopy.
Small samples of each diastereomer could be obtained by reverse-phase HPLC.
Not measured.
After purification by mass-directed HPLC.
Fig. 2Forms of reaction products. Panel A: The products 16a, ent-16d and 17a exist predominantly in pyranose forms. Panel B: the product 16c exists as a mixture of pyranose and furanose anomers.
Fig. 3Rationale for stereoselectivity of NAL-catalysed reactions between fluoropyruvate and aldehyde substrates. Panel A: S. aureus NAL in complex with fluoropyruvate with general acid Y137 and residues that have key roles in recognition and stereocontrol (T167, E192 and S208) shown (PDB: ; 5A8G). The top face (as depicted) of the Z-configured enamine is poised to react with an aldehyde substrate. Panel B: Y137A variant of E. coli NAL in compex with 4-epi-Neu5Ac (PDB: ; 4BWL). Panel C: Possible stereochemical outcomes of the reaction of the top face of the Z-configured enamine with an aldehyde substrate.